ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
17 sept. 2021 08h00 HE
|
ImCheck Therapeutics SAS
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021 First EVICTION data from checkpoint inhibitor-refractory solid tumor...
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
13 sept. 2021 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021 Marseille, France, September 13, 2021 – ImCheck Therapeutics today announced that it will present...
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
26 avr. 2021 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01 -- EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune...
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
11 mars 2021 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
11 nov. 2020 07h00 HE
|
ImCheck Therapeutics SAS
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01 Preliminary EVICTION Phase I/IIa trial data shows...
ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)
15 sept. 2020 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck Announces Investment by BB Pureos Bioventuresto Close Series B Fundraising with Total of €54 million ($64 million) Marseille, France, September 15, 2020 – ImCheck Therapeutics today announced...
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
10 sept. 2020 05h46 HE
|
ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 Company Receives FDA Approval for US IND ...
HalioDx's expertise applied to ImCheck’s EVICTION Trial
19 mai 2020 07h50 HE
|
HalioDx
HalioDx to Characterize the Immune Contexture ofPatients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial HalioDx’s immunoscoring technologies to characterize patients treated with ImCheck’s...